News Releases

News Releases

  • Aug 10, 2017

    Summary ToggleCo-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit

    Audit to prepare for eventual sales into the US market SALT LAKE CITY --(BUSINESS WIRE)--Aug. 10, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, will be
  • Aug 02, 2017

    Summary ToggleCo-Diagnostics, Inc. to Attend AACC 2017

    SALT LAKE CITY --(BUSINESS WIRE)--Aug. 2, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, will be sending Company representatives on August 2-3, 2017 , to
  • Jul 27, 2017

    Summary ToggleCo-Diagnostics, Inc. Verifies Zika CoPrimer™ Test

    SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX ) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, has completed principle design and verification of its Zika
  • Jul 25, 2017

    Summary ToggleCo-Diagnostics, Inc. Announces Joint Venture in India

    SALT LAKE CITY--( BUSINESS WIRE )--Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced today the recent incorporation of CoSara Diagnostics,
  • Jul 17, 2017

    Summary ToggleCo-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

    Salt Lake City, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends both to manufacture and sell reagents used for diagnostic tests, has completed its initial public offering and started trading
  • Jul 12, 2017

    Summary ToggleCo-Diagnostics, Inc. Announces Pricing of IPO

    Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of common stock has been priced at